452 related articles for article (PubMed ID: 31101085)
21. Impact of short-term discontinuation of ivermectin-based chemoprevention on onchocerciasis transmission in endemic settings with long history of mass drug administration.
Efon-Ekangouo A; Nana-Djeunga HC; Nzune-Toche N; Dongmo-Yemele R; Bopda J; Ongbassomben V; Sumo L; Geiger A; Nutman TB; Kamgno J
PLoS Negl Trop Dis; 2023 Apr; 17(4):e0011250. PubMed ID: 37058547
[TBL] [Abstract][Full Text] [Related]
22. Influence of health education on community participation in rapid assessment of onchocerciasis prior to distribution of ivermectin.
Shu EN; Nwadike KI; Onwujekwe EO; Ugwu OC; Okonkwo PO
East Afr Med J; 1999 Jun; 76(6):320-3. PubMed ID: 10750518
[TBL] [Abstract][Full Text] [Related]
23. Assessment of community's knowledge, attitude and practice about onchocerciasis and community directed treatment with Ivermectin in Quara District, north western Ethiopia.
Weldegebreal F; Medhin G; Weldegebriel Z; Legesse M
Parasit Vectors; 2014 Mar; 7():98. PubMed ID: 24612494
[TBL] [Abstract][Full Text] [Related]
24. Factors influencing community acceptability of mass drug administration for the elimination of onchocerciasis in the Asante Akim South Municipal, Ghana.
Kumah E; Owusu P; Otchere G; Ankomah SE; Fusheini A; Kokuro C; Mensah-Acheampong F; Atta JA; Agyei SK
PLoS Negl Trop Dis; 2023 Mar; 17(3):e0011251. PubMed ID: 37000840
[TBL] [Abstract][Full Text] [Related]
25. Impact of 3 years ivermectin treatment on onchocerciasis in Yanomami communities in the Brazilian Amazon.
Banic DM; Calvão-Brito RH; Marchon-Silva V; Schuertez JC; de Lima Pinheiro LR; da Costa Alves M; Têva A; Maia-Herzog M
Acta Trop; 2009 Nov; 112(2):125-30. PubMed ID: 19615327
[TBL] [Abstract][Full Text] [Related]
26. Onchocerciasis-associated epilepsy in the Democratic Republic of Congo: Clinical description and relationship with microfilarial density.
Siewe Fodjo JN; Mandro M; Mukendi D; Tepage F; Menon S; Nakato S; Nyisi F; Abhafule G; Wonya'rossi D; Anyolito A; Lokonda R; Hotterbeekx A; Colebunders R
PLoS Negl Trop Dis; 2019 Jul; 13(7):e0007300. PubMed ID: 31314757
[TBL] [Abstract][Full Text] [Related]
27. Reduction in the prevalence and intensity of infection in Onchocerca volvulus microfilariae according to ethnicity and community after 8 years of ivermectin treatment on the island of Bioko, Equatorial Guinea.
Mas J; Ascaso C; Escaramis G; Abellana R; Duran E; Sima A; Sánchez MJ; Nkogo PR; Nguema R; Untoria MD; Echeverria MA; Ardevol MM; de Jiménez Anta MT
Trop Med Int Health; 2006 Jul; 11(7):1082-91. PubMed ID: 16827709
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of onchocerciasis control in the Upper Denkyira East municipal in the forest area of Ghana: Responses of participants and distributors to the CDTI programme.
Agyemang ANO; Badu K; Baffour-Awuah S; Owusu-Dabo E; Biritwum NK; Garms R; Kruppa TF
Acta Trop; 2018 Sep; 185():357-362. PubMed ID: 29932933
[TBL] [Abstract][Full Text] [Related]
29. The safety and efficacy of amocarzine in African onchocerciasis and the influence of ivermectin on the clinical and parasitological response to treatment.
Awadzi K; Opoku NO; Attah SK; Addy ET; Duke BO; Nyame PK; Kshirsagar NA
Ann Trop Med Parasitol; 1997 Apr; 91(3):281-96. PubMed ID: 9229021
[TBL] [Abstract][Full Text] [Related]
30. Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial.
Opoku NO; Bakajika DK; Kanza EM; Howard H; Mambandu GL; Nyathirombo A; Nigo MM; Kasonia K; Masembe SL; Mumbere M; Kataliko K; Larbelee JP; Kpawor M; Bolay KM; Bolay F; Asare S; Attah SK; Olipoh G; Vaillant M; Halleux CM; Kuesel AC
Lancet; 2018 Oct; 392(10154):1207-1216. PubMed ID: 29361335
[TBL] [Abstract][Full Text] [Related]
31. After a decade of annual dose mass ivermectin treatment in Cameroon and Uganda, onchocerciasis transmission continues.
Katabarwa M; Eyamba A; Habomugisha P; Lakwo T; Ekobo S; Kamgno J; Kuete T; Ndyomugyenyi R; Onapa A; Salifou M; Ntep M; Richards FO
Trop Med Int Health; 2008 Sep; 13(9):1196-203. PubMed ID: 18631308
[TBL] [Abstract][Full Text] [Related]
32. Non-adherence to ivermectin in onchocerciasis-endemic communities with persistent infection in the Bono Region of Ghana: a mixed-methods study.
Otabil KB; Basáñez MG; Ankrah B; Bart-Plange EJ; Babae TN; Kudzordzi PC; Darko VA; Raji AS; Datsa L; Boakye AA; Yeboah MT; Fodjo JNS; Schallig HDFH; Colebunders R
BMC Infect Dis; 2023 Nov; 23(1):805. PubMed ID: 37974087
[TBL] [Abstract][Full Text] [Related]
33. Onchocerca volvulus infection in Tihama region - west of Yemen: Continuing transmission in ivermectin-targeted endemic foci and unveiled endemicity in districts with previously unknown status.
Mahdy MAK; Abdul-Ghani R; Abdulrahman TAA; Al-Eryani SMA; Al-Mekhlafi AM; Alhaidari SAA; Azazy AA
PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006329. PubMed ID: 29505580
[TBL] [Abstract][Full Text] [Related]
34. Primary motives for demand of ivermectin drug in mass distribution programmes to control onchocerciasis.
Abanobi OC; Chukwuocha UM; Onwuiiliri CO; Opara KC
East Afr J Public Health; 2011 Mar; 8(1):33-7. PubMed ID: 22066280
[TBL] [Abstract][Full Text] [Related]
35. Co-endemicity of loiasis and onchocerciasis in rain forest communities in southwestern Nigeria.
Ojurongbe O; Akindele AA; Adeleke MA; Oyedeji MO; Adedokun SA; Ojo JF; Akinleye CA; Bolaji OS; Adefioye OA; Adeyeba OA
PLoS Negl Trop Dis; 2015 Mar; 9(3):e0003633. PubMed ID: 25812086
[TBL] [Abstract][Full Text] [Related]
36. Phenotypic evidence of emerging ivermectin resistance in Onchocerca volvulus.
Osei-Atweneboana MY; Awadzi K; Attah SK; Boakye DA; Gyapong JO; Prichard RK
PLoS Negl Trop Dis; 2011 Mar; 5(3):e998. PubMed ID: 21468315
[TBL] [Abstract][Full Text] [Related]
37. The chemotherapy of onchocerciasis. XIII. Studies with ivermectin in onchocerciasis patients in northern Ghana, a region with long lasting vector control.
Awadzi K; Dadzie KY; Kläger S; Gilles HM
Trop Med Parasitol; 1989 Sep; 40(3):361-6. PubMed ID: 2694315
[TBL] [Abstract][Full Text] [Related]
38. A community trial of ivermectin in the onchocerciasis focus of Asubende, Ghana. I. Effect on the microfilarial reservoir and the transmission of Onchocerca volvulus.
Remme J; Baker RH; De Sole G; Dadzie KY; Walsh JF; Adams MA; Alley ES; Avissey HS
Trop Med Parasitol; 1989 Sep; 40(3):367-74. PubMed ID: 2617046
[TBL] [Abstract][Full Text] [Related]
39. Still mesoendemic onchocerciasis in two Cameroonian community-directed treatment with ivermectin projects despite more than 15 years of mass treatment.
Kamga GR; Dissak-Delon FN; Nana-Djeunga HC; Biholong BD; Mbigha-Ghogomu S; Souopgui J; Zoure HG; Boussinesq M; Kamgno J; Robert A
Parasit Vectors; 2016 Nov; 9(1):581. PubMed ID: 27842567
[TBL] [Abstract][Full Text] [Related]
40. A community-based cross-sectional study of the epidemiology of onchocerciasis in unmapped villages for community directed treatment with ivermectin in Jimma Zone, southwestern Ethiopia.
Dana D; Debalke S; Mekonnen Z; Kassahun W; Suleman S; Getahun K; Yewhalaw D
BMC Public Health; 2015 Jul; 15():595. PubMed ID: 26130117
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
